Skip to main content

Table 4 Classification of ADR (n = 246)

From: Incidence of adverse reaction of drugs used in COVID-19 management: a retrospective, observational study

ADR according to SOC

Incidence of ADR

Time to onset

Acute (within 60 min)

Subacute (1 to 24 h)

Latent (after 2 days)

Blood and lymphatic system disorders

     Anaemia

2 (0.8%)

0

1

1

Cardiac disorders

     QT prolongation

34 (13.8%)

0

9

25

     Bradycardia

4 (1.6%)

0

1

3

     ST elevation

1 (0.4%)

0

0

1

     Palpitation

1 (0.4%)

0

0

1

Gastrointestinal disorders

     Diarrhoea

76 (30.9%)

0

49

27

     Nausea and vomiting

27 (11.0%)

1

7

19

     Abdominal pain

4 (1.6%)

0

2

2

Hepatobiliary disorders

     Hyperbilirubinaemia (without jaundice)

77 (31.3%)

0

17

60

     Elevated liver transaminases

6 (2.4%)

0

0

6

     Hyperbilirubinaemia (with jaundice)

5 (2.0%)

0

3

2

     Elevated alkaline phosphatase

1 (0.4%)

0

0

1

Nervous system disorders

     Giddiness

3 (1.2%)

1

0

2

     Headache

1 (0.4%)

0

1

0

Renal and urinary disorders

     Acute kidney injury

2 (0.8%)

0

1

1

Skin and subcutaneous tissue disorders

     Rash

2 (0.8%)

0

1

1

  1. Incidence of ADR is reported as n (%), where % is calculated by number of ADR/n